| Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer (NCT05007938) | Betta Pharmaceuticals Co., Ltd. | 2021-08-12 |
| Gut Microbiota and Cancer Immunotherapy Response (NCT04682327) | Shanghai Zhongshan Hospital | 2021-08-12 |
| Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations (NCT04923906) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2021-08-11 |
| Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 (NCT04787042) | Simcha IL-18, Inc. | 2021-08-06 |
| A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC) (NCT04964479) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-08-06 |
| Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) (NCT04956692) | Merck Sharp & Dohme LLC | 2021-08-05 |
| A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors (NCT04913285) | Pierre Fabre Medicament | 2021-08-04 |
| Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer (NCT04791839) | Washington University School of Medicine | 2021-08-04 |
| Copenhagen Master Observational Trial (NCT05145244) | Rigshospitalet, Denmark | 2021-08-01 |
| Hypofraction Radiotherapy for Locally Advanced Non-small Cell Lung Cancer (NCT05269485) | Anhui Provincial Hospital | 2021-08-01 |
| The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC. (NCT04777084) | Hunan Province Tumor Hospital | 2021-08-01 |
| Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy (NCT04968002) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2021-08-01 |
| FHND9041 Versus Afatinib for Non-small Cell Lung Cancer (NCT06759857) | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | 2021-08-01 |
| Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations (NCT05507606) | Tianjin Medical University Cancer Institute and Hospital | 2021-08-01 |
| Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients (NCT04967079) | Shanghai Chest Hospital | 2021-08-01 |
| Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer (NCT05016544) | Sun Yat-sen University | 2021-07-28 |
| A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC (NCT04849273) | Turning Point Therapeutics, Inc. | 2021-07-28 |
| Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC (NCT04786093) | University of Texas Southwestern Medical Center | 2021-07-27 |
| Osimertinib for Advanced EGFR-positive NSCLC Patients (NCT05037331) | National University Hospital, Singapore | 2021-07-22 |
| A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors (NCT05329298) | Betta Pharmaceuticals Co., Ltd. | 2021-07-21 |
| Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6) (NCT05712902) | Dizal Pharmaceuticals | 2021-07-19 |
| Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations (NCT05445791) | Instituto Nacional de Cancerologia de Mexico | 2021-07-15 |
| Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors (NCT04985604) | Day One Biopharmaceuticals, Inc. | 2021-07-15 |
| Lung Perfusion PET / CT Using Ga68-MAA for Preservation of Lung Function During Stereotactic Pulmonary Radiation Therapy (NCT04942275) | University Hospital, Brest | 2021-07-15 |
| A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation (NCT04951648) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2021-07-15 |
| EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (NCT04892472) | NovoCure GmbH | 2021-07-12 |
| Breath Combined With CT for Diagnoses of Pulmonary Nodules (NCT04948047) | Peking University People's Hospital | 2021-07-10 |
| A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment (NCT04872634) | NKMAX Co., Ltd. | 2021-07-08 |
| Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy (NCT04037462) | VA Office of Research and Development | 2021-07-07 |
| A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC (NCT04950400) | Beijing Chest Hospital | 2021-07-07 |
| Using ctDNA to Detect Minimal Residual Disease After Lung Cancer Resection (NCT05254782) | University Health Network, Toronto | 2021-07-06 |
| The Effects of an Nutritional Intervention on PD-1 ICI in NSCLC (NCT05902260) | Joachim Aerts, MD PhD | 2021-07-06 |
| Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) (NCT04886804) | Boehringer Ingelheim | 2021-07-02 |
| A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors (NCT04841538) | Elpiscience Biopharma, Ltd. | 2021-07-01 |
| SHR-1701 Combined With Fluzoparib in Lung Squamous Cell Carcinoma (NCT04937972) | Hunan Province Tumor Hospital | 2021-07-01 |
| A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors (NCT04875806) | NextCure, Inc. | 2021-06-30 |
| A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer (NCT04870112) | AstraZeneca | 2021-06-28 |
| Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION) (NCT04923802) | GeneCast Biotechnology Co., Ltd. | 2021-06-24 |
| The Research Plan of Taiwan Precision Medicine (NCT04849481) | National Health Research Institutes, Taiwan | 2021-06-23 |
| Molecular Profiling of Exosomes in Tumor-draining Vein of Early-staged Lung Cancer (NCT04939324) | University Hospital, Limoges | 2021-06-21 |
| A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer (NCT04866017) | BeiGene | 2021-06-17 |
| Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors (NCT04892017) | Deciphera Pharmaceuticals, LLC | 2021-06-15 |
| Onco-primary Care Networking to Support TEAM-based Care (NCT04258813) | Duke University | 2021-06-14 |
| Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies (NCT04913337) | NGM Biopharmaceuticals, Inc | 2021-06-09 |
| Study of XB002 in Subjects With Solid Tumors (JEWEL-101) (NCT04925284) | Exelixis | 2021-06-07 |
| Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment. (NCT06277388) | Sun Yat-sen University | 2021-06-05 |
| An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer (NCT06542731) | Ono Pharmaceutical Co., Ltd. | 2021-06-01 |
| Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients (NCT04980716) | Sun Yat-sen University | 2021-06-01 |
| MR-Linac Guided Adaptive FSRT for Brain Metastases From Non-small Cell Lung Cancer (NCT04946019) | Sun Yat-sen University | 2021-06-01 |
| A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression (NCT04970693) | Sun Yat-sen University | 2021-06-01 |
| AB122 Platform Study (NCT04999761) | Taiho Pharmaceutical Co., Ltd. | 2021-06-01 |
| A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors (NCT04903873) | Eutilex | 2021-05-31 |
| BESPOKE Study of ctDNA Guided Immunotherapy (NCT04761783) | Natera, Inc. | 2021-05-28 |
| Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC (NCT04768075) | Guangdong Association of Clinical Trials | 2021-05-28 |
| Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 (NCT04795713) | Molecular Templates, Inc. | 2021-05-27 |
| Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer (NCT04789486) | Dana-Farber Cancer Institute | 2021-05-27 |
| A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors (NCT04895709) | Bristol-Myers Squibb | 2021-05-27 |
| A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer (NCT04746924) | BeiGene | 2021-05-24 |
| A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC (NCT04900363) | Akeso | 2021-05-21 |
| A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer (NCT04905316) | Memorial Sloan Kettering Cancer Center | 2021-05-21 |
| Alectinib in Neo-adjuvant Treatment of Stage III NSCLC (NCT05015010) | Gruppo Oncologico Italiano di Ricerca Clinica | 2021-05-20 |
| Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations (NCT05103605) | AstraZeneca | 2021-05-12 |
| Lung Cancer With Copanlisib and Durvalumab (NCT04895579) | Zhonglin Hao | 2021-05-12 |
| Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC (NCT04875585) | Medical University Innsbruck | 2021-05-12 |
| Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia (NCT04803305) | Pfizer | 2021-05-11 |
| A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations (NCT04816838) | Yonsei University | 2021-05-10 |
| Consolidation Conventional Radiotherapy + Stereotactic Body Radiotherapy at 3 Months After First-line Chemotherapy in Stage IV Oligometastatic Non-small Cell Lung Cancer (NCT04758481) | University Hospital Ostrava | 2021-05-04 |
| Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors (NCT04902872) | Cybrexa Therapeutics | 2021-05-03 |
| the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer (NCT04978753) | Li-kun Chen | 2021-05-01 |
| Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models (NCT04646837) | Peking Union Medical College Hospital | 2021-05-01 |
| Radiation-induced Cardiac Toxicity After Non-small Cell Lung Cancer Radiotherapy (NCT04867564) | Military Institute od Medicine National Research Institute | 2021-05-01 |
| Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations (NCT04687241) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2021-04-30 |
| JAB-3068 Activity in Adult Patients With Advanced Solid Tumors (NCT04721223) | Jacobio Pharmaceuticals Co., Ltd. | 2021-04-26 |
| TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC) (NCT05441956) | Shenzhen TargetRx Co., Ltd. | 2021-04-23 |
| Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor (NCT05278364) | Shouyao Holdings (Beijing) Co. LTD | 2021-04-23 |
| Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer (NCT04726215) | CellSight Technologies, Inc. | 2021-04-15 |
| Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer (NCT04735068) | Abramson Cancer Center at Penn Medicine | 2021-04-09 |
| Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) (NCT04585477) | Stanford University | 2021-04-08 |
| The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2) (NCT04818983) | Chugai Pharmaceutical | 2021-04-07 |
| Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma (NCT04725448) | Sichuan Cancer Hospital and Research Institute | 2021-04-06 |
| Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients (NCT04470674) | Shirish M Gadgeel | 2021-04-06 |
| LIQUIK: LIQUId Biopsy for Detection of Actionable Genomic BiomarKers in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (NCT04703153) | Lucence Health Inc. | 2021-04-05 |
| Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC (NCT04754815) | Shirish Gadgeel | 2021-04-01 |
| Efficacy and Safety of Camrelizumab in Real-World Prospective Study (NCT04793139) | Guangdong Association of Clinical Trials | 2021-04-01 |
| Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest. (NCT05044728) | Sichuan Cancer Hospital and Research Institute | 2021-04-01 |
| Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery (NCT04536675) | Samsung Medical Center | 2021-04-01 |
| Preoperative Lymph Node Staging With EBUS-TBNA in Clinical N0 Non Small-cell Lung Cancer (NCT04828850) | European Institute of Oncology | 2021-04-01 |
| Feasibility Study of the Aliya System in the Treatment of Early Stage Non-small Cell Lung Cancer (NCT04732520) | Galvanize Therapeutics, Inc. | 2021-03-31 |
| Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors (NCT03915678) | Institut Bergonié | 2021-03-31 |
| Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008) (NCT04772287) | Shanghai Pulmonary Hospital, Shanghai, China | 2021-03-31 |
| Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (NCT04644237) | Daiichi Sankyo | 2021-03-19 |
| A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors (NCT04731467) | Famewave Ltd. | 2021-03-19 |
| A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (NCT04951635) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2021-03-18 |
| CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC (NCT04681131) | BioAtla, Inc. | 2021-03-17 |
| A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC (NCT04550104) | University of Leeds | 2021-03-17 |
| SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II (NCT04480372) | Swiss Cancer Institute | 2021-03-17 |
| Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC (NCT04797806) | Tianjin Medical University Cancer Institute and Hospital | 2021-03-12 |
| Intratumoral Cisplatin for Resectable NSCLC (NCT04809103) | University of Vermont | 2021-03-08 |
| BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation (NCT04775095) | Intergroupe Francophone de Cancerologie Thoracique | 2021-03-08 |
| Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer (NCT04742192) | AstraZeneca | 2021-03-04 |